News

Fierce Pharma43m
Fierce Pharma Asia—GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy
GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...
Regeneron Beats Second-Quarter Results Estimates on Dupixent Sales Boost
(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by ...